Stock Financial Ratios


INVA / Innoviva, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price13.06
Volume637,000.00
Market Cap ($M)1,556.15
Enterprise Value ($M)2,328.51
Book Value ($M)-352.99
Book Value / Share-2.86
Price / Book-6.98
NCAV ($M)358.95
NCAV / Share2.91
Price / NCAV4.37
Income Statement (mra) ($M)
Revenue133.57
EBITDA108.99
Net Income0.00
Balance Sheet (mrq) ($M)
Cash & Equivalents138.42
Cash / Share1.12
Assets390.97
Liabilities613.93
Quick Ratio9.88
Current Ratio9.88
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.00
Identifiers and Descriptors
CUSIP45781M901
Central Index Key (CIK)1080014
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
45781M101
45781M951
Share Statistics
Common Shares Outstanding (M)108.02
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share1.12
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Additional Paid In Capital Per Share10.84
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Long Term Debt Per Share4.69
Assets Current Per Share1.79
Liabilities And Stock Equity Per Share3.17
Cash Per Share1.12
Liabilities Per Share4.98
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Equity Per Share-1.81
Treasury Stock Per Share0.00
Assets Per Share3.17
Inventory Per Share0.00
Debt Per Share4.69
Liabilities Current Per Share0.27
Assets Other Non Current Per Share0.00
Retained Earnings Per Share-12.64
Intangibles Per Share0.00
Goodwill Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Liabilities Other Non Current Per Share0.01

Related News Stories

Corporate News Blog - GlaxoSmithKline and Innoviva’s Trelegy Ellipta Gets Marketing Authorization for the Treatment of COPD in Europe

2h accesswire
LONDON, UK / ACCESSWIRE / November 20, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK) ("GSK"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=GSK. The leading research-based pharmaceutical and healthcare Company, announced on November 16, 2017, with Innoviva Inc. (45-0)

Theravance Shares Rise on Approval of Glaxo's COPD Therapy

2017-11-17 zacks
Theravance Biopharma, Inc.’s (TBPH - Free Report) shares rose almost 6.5% on Thursday following the approval of GlaxoSmithKline plc’s (GSK - Free Report) chronic obstructive pulmonary disease ("COPD") therapy, Trelegy Ellipta in Europe. Investors cheered the approval as Theravance has an economic interest on the royalties that Glaxo will pay to its partner Innoviva, Inc. (INVA - Free Report) on global sales of Trelegy Ellipta. (36-0)

Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

2017-11-17 zacks
GlaxoSmithKline plc (GSK - Free Report) and partner Innoviva, Inc. (INVA - Free Report) announced that their triple combination therapy was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with chronic obstructive pulmonary disease (COPD). (36-0)

Innoviva's (INVA) CEO Michael Aguiar on Q3 2017 Results - Earnings Call Transcript

2017-10-26 seekingalpha
Ladies and gentlemen, good afternoon. At this time, I’d like to welcome everyone to the Innoviva Third Quarter 2017 Financial Results Webcast and Conference Call. During the presentation, all participants will be in a listen-only mode. A question-and-answer session will follow the Company’s follow remarks. [Operator Instructions] I’ll repeat these instructions after management completes their prepared remarks. (42-1)

AstraZeneca's Bevespi Improves Lung Function in Phase III Study

2017-09-27 zacks
AstraZeneca plc (AZN - Free Report) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). (74-0)

CUSIP: 45781M901